Tag: JVN

Health Care

DKSH Supports Growth for Vitabiotics in Hong Kong and Malaysia

admin

DKSH, the leading Market Expansion Services provider with a focus on Asia, and Vitabiotics, Britain’s largest and fastest growing major vitamin supplement company, has signed an agreement to expand the firm’s product range into Hong Kong and Malaysia.

BANGKOK, April 8, 2015 /PRNewswire/ — DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, will provide marketing, sales, distribution, logistics and regulatory services for Vitabiotics in Hong Kong and Malaysia. The agreement is an extension of a collaboration that started in Taiwan in 2011.

DKSH will broaden Vitabiotics’ already established market position and product range in Hong Kong on offer by leveraging its reach and deepening distribution to more pharmacy outlets. The Vitabiotics range is also undergoing approval by authorities in Malaysia.

According to a recent study by Roland Berger Strategy Consultants, the Market Expansion Services market for over-the-counter healthcare products in Hong Kong is expected to grow by 5-6% annually between 2014 and 2019. Malaysia is expected to see a slightly higher growth rate of 6-7% growth per year over the same period.

“The diverse Asian market shows excellent long term growth potential for Vitabiotics’ products. Working with our regional partner DKSH allows us to accelerate our growth and enter new strategic markets at the same time. While we can focus on our core strengths, DKSH’s strong commitment to compliance and governance gives us the security that the expansion of our business is in safe hands,” said Robert Taylor, Vice President, Vitabiotics.

“Our regional reach and integrated services give Vitabiotics the convenience of working with one strategic partner across multiple markets. With the insights and commercial capabilities of our local experts and our broad capillary distribution, we are confident to spur further growth for Vitabiotics in Asia,” said Andrew Frye, Head of Business Healthcare, DKSH.

The agreement will strengthen DKSH’s market position in Asia over time.

About Vitabiotics

Vitabiotics has pioneered advances in nutritional healthcare for 45 years, a British company committed to human health and research. As the UK’s No.1 vitamin company, Vitabiotics has created a unique portfolio of products at the forefront of scientific developments in key sectors, with no fewer than 8 brands in the top 18 VMS brands in the UK, including Pregnacare, Osteocare, Wellman and Wellwoman. Vitabiotics is widely acknowledged as leaders in innovation and in 2013 became the first vitamin company to receive the Queen’s Award for Innovation, awarded for its ground breaking clinical research.

As the fastest growing major vitamin company in the UK, Vitabiotics exports to over 100 countries, and has twice received the Queen’s Awards for International Trade. Designed to provide maximum efficacy by supporting the human body in its own natural processes, each product is developed using the latest research available and is produced to the highest pharmaceutical standards.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term “Market Expansion Services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets.

Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 750 business locations in 35 countries — 720 of them in Asia — and 27,600 specialized staff, DKSH generated net sales of CHF 9.8 billion in 2014.

In 2015, DKSH celebrates its 150th anniversary. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia, and is deeply rooted in communities and businesses across Asia Pacific.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products, as well as medical devices. With 150 business locations in 14 countries and around 9,200 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of around CHF 4.5 billion in 2014.

Fashion HOU

An Unlikely Collaboration – Fragrance Du Bois teams up with Arabic singer to create ‘Life’s Treasure’ A Song for Oud

admin

SINGAPORE, April 3, 2015 /PRNewswire/ — In what must surely be a world’s first, Fragrance Du Bois (a French perfume house and retailer specialising in the use of sustainable Oud), and Nadeem Nour (one of the Middle East’s best known and most respected singer/songwriters), came together to produce a musical enterprise close to both their hearts.

Nadeem Nour is a well-renowned Jordanian singer. The reason for his artistic name "Nadeem Nour" is that it is said that from the first moment you hear him, you can feel the light in his voice

Nadeem Nour is a well-renowned Jordanian singer. The reason for his artistic name “Nadeem Nour” is that it is said that from the first moment you hear him, you can feel the light in his voice

“About a year ago I was introduced by a friend to a gentleman from Iran who had just returned from visiting Thailand and Malaysia. While he was there, he discovered the agarwood (Oud) plantations owned and managed by Asia Plantation Capital,” said Nadeem Nour in Dubai recently. “I became fascinated when I learned that not only was much of the Oud that we take for granted coming from illegal sources — not only in the past, but also today — but that it was in danger of extinction in the wild as a result.”

“Having grown up in Jordan, with Oud being very much a part of my daily life, and that of my family, I felt guilty when I realised that like many others, I could have spent my entire life taking Oud for granted, without ever wondering where it actually came from. The thought that I may actually be part of driving an illegal industry was horrifying.”

Nadeem continued, “I became deeply concerned, and as I feel passionately for the world in which we live, I decided to do my own research and find out the facts. I quickly realised — after talking to friends, and doing some research on the internet and looking at several news reports — that we had reached a situation where Oud, in the wild, was soon to be no more. I also realised that I was not alone in my ignorance. Hardly any of my friends were aware of Oud in terms of where it came from, and the threats it faces. Like me, they pretty much took it for granted.”

Nadeem went on to detail how important Oud was in Arabic culture and heritage, further lamenting the fact that the source was often unreliable. International fashion houses and perfume brands are now putting Oud into their products in increasing amounts, creating pressure on future supplies of the mystical substance.

Agarwood, and Oud (the oil derived therefrom), is now on the CITES (the Convention on International Trade in Endangered Species of Wild Flora and Fauna), list of endangered species, and as such, all trade has to be legal, certified, and sustainable. Demand is huge, far outstripping supply, and only sustainable plantations are the way forward.

“Asia Plantation Capital and their sister company Fragrance Du Bois,” continued Nadeem, “are two companies leading the way in making this industry transparent and sustainable for the benefit of all users of Oud – not only in the Gulf region, but also across the world. I decided that this story had to be told, and for me the only way to tell the story was through traditional Arabic words and music.”

Nadeem Nour has been a rising star on the Middle Eastern music scene for several years since appearing in the Jordanian Pop Idol show, and has built up a loyal following for his beautiful singing voice, heartfelt lyrics, and the music he performs across the Gulf. Dubbed ‘Nadeem Nour’ by Tarek Al Arians, the artist has evolved to the point at which listeners can feel the ‘light in his voice’, from the first moment you hear him sing.

Fragrance Du Bois, Asia Plantation Capital and Nadeem Nour earnestly hope that the light in his voice helps to tell a story that we all need to hear, and that ‘Life’s Treasure’ imparts a vital message when it comes to protecting a species that could all too easily have been lost forever.

A video of the song can be watched here http://youtu.be/PsV0Ku4vWDU

About Fragrance Du Bois

Fragrance Du Bois is a niche luxury perfume house working closely with sustainable plantations in Asia, bringing exciting new 100% organic Oud oil based fragrances to exclusive markets worldwide. Sustainably sourcing the finest raw materials across the globe, working with French perfumers to create a full range of products, and also providing bespoke fragrance services, Fragrance Du Bois is personal luxury with a conscience. With exclusive fragrance lounges around the world, in Dubai, Hong Kong, Thailand, Malaysia and Singapore, Fragrance Du Bois creates only the finest experience in bespoke perfumery.

Fragrance Du Bois is known as Parfums Du Bois in France and in non-French speaking markets, as Fragrance Du Bois.

About Asia Plantation Capital

Quick facts:

  • US$ 600 million – combined value of assets owned and under management
  • US$ 53.5 million – turnover in the last financial year
  • US$ 100 million – turnover forecast for current financial year
  • 2,000,000 – Aquilaria trees today, on Agarwood plantations.

Asia Plantation Capital (APC) is the owner and operator of a diverse range of commercial plantation and farming businesses across the Asia-Pacific region and around the world, and is part of the Asia Plantation Capital Group of associated companies. Its focus is on multicultural and diverse plantation projects geared to the domestic and commercial demands of the countries in which it operates. Working closely with, and supporting local communities, is an underlying core principle of the APC business, providing social and cultural support, as well as investment, to move these communities away from deforestation and illegal logging activities, previously seen as a main source of income in some regions of Asia. Established officially in 2008 (although operating privately since 2002) the group now has plantation and agricultural projects on four continents, with operational projects at various stages in Thailand, Malaysia, China, Laos, India, Cambodia, Sri Lanka, Myanmar, Vietnam, North America and Europe.

Promoting the use of sustainable and certified wood is the best way of preventing deforestation, protecting biodiversity, and combatting poverty in the tropical rainforest regions. For the yachting sector (a major user of teak) which strives for excellence and which is already involved in environmental efforts, this is also a way of ensuring that no wood from illegal logging is used.

CONTACT: Stéphanie du Ché, PR & Media Manager Europe, stephanie.duche@asiaplantationcapital.com, +33 616 361 108; Adrian Heng, Group Marketing Director, adrian.heng@asiaplantationcapital.com, +65 6299 1778

Photo – http://photos.prnasia.com/prnh/20150403/8521502133

ENT Fashion

foodpanda Teams Up With Food Aid Foundation – Give A Little, Help A Lot

admin

Food Aid Foundation and foodpanda Malaysia team up to raise funds for food for Persatuan Rumah K.I.D.S. Orphanage in Malaysia.

KUALA LUMPUR, Malaysia, April 3, 2015 /PRNewswire/ — foodpanda hopes to help people learn about the importance of eating healthy and provide some basic knowledge about nutrition. With the “give a little, help a lot” initiative we would like to show that it takes very little effort to make significant changes. Together with Food Aid Foundation, our project is in the best hands: Food Aid Foundation will take care of the distribution and the transportation of the food.

“Our goal is to collect EUR1,000 (EUR1 = MYR3.94), to help cover two months of groceries for the orphanage. The collected money will go to Food Aid Foundation’s official fund raising account. They will buy the most necessary food stuffs for Rumah K.I.D.S Orphanage from the collected amount,” says Sidney, Country Manager of foodpanda Malaysia.

About Rumah K.I.D.S Orphanage

Persatuan Rumah Kanak-Kanak Ini Di Sayangi (Rumah K.I.D.S) began its operations in 1991. They are located at 7, Jalan Durian, Kawasan 6, 41100 Klang, Selangor. It is a registered non-profit charitable home for orphans and abandoned children. It is registered with the Registrar of Society and subsequently with Jabatan Kebajukan Masyarakat Malaysia and other related governmental departments.

The children are separated in two homes, based on gender. They between 4 to 18 years old. The orphanage needs support in order to provide food security for the children and assistance to cover the utility bills.

About foodpanda

foodpanda group is the leading global food delivery marketplace, active in 39 countries on five continents. The company enables restaurants to become visible in the online and mobile world and provides them with the latest online technology. For consumers, foodpanda/hellofood offer the convenience to order food online and with the widest gastronomic range, from which they can choose their favourite meal on the web or via the app.

Look us up at:
Website: www.foodpanda.my
Facebook: facebook.com/FoodpandaMalaysia

For more information on this press release, or to arrange interviews with company management, please contact:

Sidney Ng
Country Manager, Malaysia
Unit D-3A-08, Level 3A, Block D,
Southgate Commercial Centre,
No.2 Jalan Dua off Jalan Chan Sow Lin, 55200 Kuala Lumpur
Tel: +6016-3062330
Email: s.ng@foodpanda.my

Trisha Ang
Marketing Manager
Unit D-3A-08, Level 3A, Block D,
Southgate Commercial Centre,
No.2 Jalan Dua off Jalan Chan Sow Lin, 55200 Kuala Lumpur
Tel: +6016-7252996
Email: t.ang@foodapanda.my

Health Care

Johnson & Johnson Innovation – JJDC Makes $15 Million Investment in Vivo Capital Fund

admin

SINGAPORE, April 2, 2015 /PRNewswire/ — Johnson & Johnson Innovation – JJDC, Inc. (JJDC) today announced a USD $15 million commitment to Vivo Capital Fund VIII (“Vivo VIII”).  Vivo Capital is an investment firm focused on investing in and developing healthcare companies in the U.S. and China.

This investment in Vivo VIII provides late stage venture and early stage growth capital to be invested in the United States and China. This investment helps bridge two of the world’s largest healthcare markets and enables cross-country relationships that will allow for market expansion and access to new products. The fund aims to combine the innovation and expertise with the growth and capital of the different regions using their presence in both regions.

JJDC is the first healthcare venture group to invest in Vivo VIII. With headquarters in Palo Alto, Shanghai, and Beijing, Vivo Capital maintains a long history of partnership with entrepreneurs and industry members in both countries.

“We are excited about our investment in Vivo VIII as part of our strategy to support and advance innovation in the Asia Pacific region,” said Vladimir Makatsaria, Company Group Chairman of Medical Devices, Asia Pacific for Johnson & Johnson. “Vivo Capital’s differentiated strategy and depth of experience in China and the United States provides us a greater window on the emerging science in China, and opportunities to invest in these promising companies.”  

Vivo Capital has managed a total of seven funds in the last 17 years. They have participated in seven IPOs in China, and have coordinated two of the largest medical device exits in Chinese history with China Kanghui and Trauson. In the United States, the fund has managed multiple exits, including Ceptaris, Neomend, Vicept, and Rempex. Given the room for continued industry growth in China, investment opportunities remain abundant, with total healthcare expenditure set to grow to USD $1 trillion by 2020, with an average growth rate of 18% every year since 2012.

About Johnson & Johnson Innovation – JJDC

About Johnson & Johnson Innovation – JJDC, Inc. is the venture capital subsidiary of Johnson & Johnson that has been investing since 1973 in medical device, diagnostic, pharmaceutical and consumer health areas.  Our goal is to create opportunities that meet the strategic needs of Johnson & Johnson while providing visibility to innovative emerging technology, businesses and business models.  JJDC measures the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth opportunities for the Johnson & Johnson Family of Companies.  JJDC is interested in opportunities that address significant unmet medical needs, have clear competitive advantages, IP protection, an executable clinical and commercialization plan and are led by experienced management.  JJDC invests in companies across the continuum from early stage seed investments to advanced stages of series venture management.  Our investment teams are based in Johnson & Johnson Innovation’s four regional innovation centers in Boston, California, London and Asia Pacific.  For more information, please visit www.jnjinnovation.com.

(This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation – JJDC, Inc. and/or Johnson & Johnson.  Risks and uncertainties include, but are not limited to, the potential that the expected benefits and opportunities of this investment may not be realized. Investments in externally sourced innovation are inherently risky, with no guarantee of success. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Neither Johnson & Johnson Innovation – JJDC, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments).

Health Care

Capita Healthcare Decisions Partner With Medibank to Deliver Safe, Consistent Health Advice for Australians

admin

BASINGSTOKE, UK, April 2, 2015 /PRNewswire/ — Capita announces a partnership with Medibank, a healthcare company providing private health insurance and health solutions to almost 3.9 million people throughout Australia and New Zealand.

Logo: http://photos.prnewswire.com/prnh/20150402/736790

As part of a wider relationship, Capita will provide Medibank with its market leading TeleGuides content set, which Medibank have localised for the Australian market. The localisation of the content means Medibank can offer the population tailored, appropriate care advice – facilitating access to the best health advice for service users wherever they may be located.

This will support a team of clinicians to deliver safe, consistent health advice to service users.

The clinical content provided by Capita has been through a robust clinical governance process, and Capita have experience of over 85 million patient encounters worldwide without clinical incident – including powering the NHSDirect helpline in the UK.

The content is written and customised through Capita’s Decision Management Software (DMS) composer. This allows users to both create clinical content and decision pathways, and to present them either by phone, face to face, or on the web and mobile. Users can create and edit content quickly, giving the ability to safely and efficiently implement new and innovative solutions that reflect the latest clinical practice. The highly scalable software has the capability to integrate with any other technology, such as CRM systems, through the open application programming interface (API).  

Richard Atkins, general manager, international, comments on the new partnership:

“Capita Healthcare Decisions has had a presence in Australasia for a number of years. However, the opportunity to now partner with Medibank across the region and into Asia on multi-national, multi-channel decision support services is really exciting. Bringing together our market leading software and clinical content together with Medibank’s longstanding track record in delivering a range of clinical services provides a catalyst for new health models of care for citizens in the region.”

Dermot Roche, Medibank general manager of telephone, online & population health said:

“The new partnership with Capita will add to Medibank’s reputation of providing innovative health solutions to both the members of Medibank and the broader Australian population who access health advice when they need it most.  

“We are delighted to partner with Capita and look forward to working with them to deliver appropriate, safe and efficient healthcare advice to Australians,” said Mr Roche.

Note to editors:      

About Capita’s Healthcare Decisions business (formerly Clinical Solutions)      

We transform healthcare decision making.

Our solutions support healthcare providers to make better decisions about their patients, and empower individuals to make better decisions about their own health and wellbeing. Over the past 16 years, our decision support software applications have been used by some of the world’s leading healthcare providers to power over 85m patient transactions. Capita Healthcare Decisions brings together clinical expertise and Silicon Valley innovation to power decision support which delivers more for less and is underpinned by three principles: safe, connected, useful.  For more information go to http://www.capitahealthcaredecisions.com.

Media enquiries:     

Katy Stoneham
Marketing Manager
Capita Healthcare Decisions
Email: katy.stoneham@capita.co.uk

Emily Fear-Gook
Medibank Media and Communications Adviser
Email: Emily.fear-gook@medibank.com.au

ENT Fashion

Cachet Hotel Group And Drai’s Announce Formation Of Joint Venture Nightlife Company

admin

– The new venture will target hotels and mixed-use developments with a focus on creating fully integrated nightlife and entertainment destinations.

HONG KONG, March 31, 2015 /PRNewswire/ — Cachet Hotel Group (CHG) and Drai’s Enterprises (Drai’s) today announced the formation of a joint venture nightlife management company, to be named Drai’s Asia. The new venture will focus on the development and management of Drai’s nightclubs, supper clubs, bars, ultra lounges and beach clubs throughout Asia Pacific in destination cities and resorts.

Drai's

Drai’s

“We are pleased to partner with creative geniuses, Victor Drai and Michael Gruber, who have a proven track record in creating nightlife destinations,” said Alexander Mirza, President and CEO of Cachet Hotel Group, “This new venture will serve Asia’s growing demand for nightlife. We look forward to debuting Drai’s within CHG hotels and in other properties.”

Victor Drai is the epitome of self-starting entrepreneurial success; from his humble beginnings to his stature as being a Las Vegas nightlife impresario. From business owner to movie producer to restaurant owner and more, today Drai is regarded by many as the “father of the Las Vegas’ nightlife scene.”  A nightlife mogul, Victor Drai is the creator and founder of Las Vegas’ mega clubs Tryst and XS at Wynn, and the visionary owner behind Drai’s Afterhours and Drai’s Beach Club·Nightclub at The Cromwell in Las Vegas. Prior to solidifying his firm foothold in the Las Vegas nightlife scene, Drai forayed into the entertainment industry where he hit cinematic gold as the sole producer of hits such as The Woman in Red, The Man with One Red Shoe, Folks, The Bride and the blockbuster Weekend at Bernie’s. 

The partnership with Cachet comes one year after Drai’s opened their flagship Las Vegas Drai’s Beach Club·Nightclub venue with Caesars Entertainment, and on the heels of Drai’s announcing their flagship ultra lounge set to open in the much anticipated Trump Hotel and Residences in Vancouver. 

“Victor and I are very excited about expanding into Asia Pacific with Cachet, an innovative lifestyle hotel group that is growing across the region,” said Michael Gruber, President of Drai’s Enterprises and CEO of Drai’s Asia, “Drai’s Asia will bring our award-winning brands and operation expertise to developers throughout China, Thailand and across Southeast Asia.”

The venture’s first two projects will debut in Chengdu at the Cachet Hotel in 2016 and in Bangkok at the much-anticipated Cachet Deluxe Hotel in 2017. The Chengdu and Bangkok venues will be Drai’s first locations outside North America.

About Cachet Hotel Group:

Cachet Hotel Group (CHG) is a Hong Kong-based hotel management company. CHG’s mission is to be the most innovative and socially responsible hospitality company in Asia. With numerous projects under development, CHG is focused on establishing properties in Greater China, Southeast Asia, Northeast Asia and the United States. For more information, please go to www.cachethotelgroup.com

About Drai’s Enterprises – Drai’s Beach Club – Nightclub/Drai’s Afterhours/Indigo Lounge:

Drai’s Enterprises owns and operates three exclusive Las Vegas nightlife venues in Las Vegas — Drai’s Beach Club – Nightclub/Drai’s Afterhours/Indigo Lounge.  Drai’s nightlife venues are strategically located across from Caesars Palace and The Bellagio, at the corner of Las Vegas Blvd. and Flamingo Blvd. on the rooftop and below ground of Caesars Entertainment’s 188 room and suite hotel The Cromwell and the classic Bally’s Hotel/Casino. With unrivaled views, Drai’s Beach Club – Nightclub takes entertainment and nightlife to new heights. The Strip’s only rooftop Beach Club includes multiple pools shaded by 10 towering palm trees, a variety of cabanas and bungalows, two full-service bars and a gourmet kitchen. Drai’s Nightclub is a dazzling, multi-level club with an expansive dance floor, massive LED lighting systems, and modern technology featuring more than 4,000 square feet of the most state of the art high definition LEDs in production, including a towering 80-sided LED disco ball – the only one of its kind, and the opportunity to detonate custom rooftop firework shows.  Additionally, the legendary Drai’s Afterhours is back in its original location for its 16th year and now brings late night/early morning entertainment to the Strip six nights a week.  Indigo Lounge, located at the iconic Bally’s Hotel/Casino, is a sexy, plush and beautifully designed lounge and bar on the casino floor at Bally’s Las Vegas. Once a main-stay of the Las Vegas experience, the casino lounge concept has all but disappeared, but with the arrival of Indigo Lounge, Victor Drai brought the classic, sophisticated Las Vegas icon back to the center of the Las Vegas Strip.

For more information, visit www.draislv.com and follow Drai’s at Facebook at www.facebook.com/draislv and on Twitter at www.twitter.com/draislv and Instagram @draislv

Photo – http://photos.prnasia.com/prnh/20150330/0861502392

Health Care

Yale University and Novogen Release Data on Cantrixil Mode of Action

admin

Key data confirming Cantrixil kills ovarian cancer stem cells

Unique action of inhibiting pro-survival mechanisms and promoting pro-death mechanisms

SYDNEY, March 30, 2015 /PRNewswire/ — US-Australian drug discovery company, Novogen Ltd, (ASX:NRT; NASDAQ:NVGN) and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.

In both in vitro and in animal studies, Cantrixil, has proved highly effective at killing human ovarian stem (tumor-initiating) cells, cells that otherwise are highly resistant to standard of care cytotoxic drugs and which generally are believed to be responsible for diseases recurrence following initial therapy. Researchers have been keen to understand how the active ingredient in Cantrixil, TRXE-002, is able to achieve this effect where other drugs have failed.

The data shows that Cantrixil specifically activates the JNK-Jun pathway leading to mitochondrial damage and the induction of genes associated with cell death (apoptosis). In addition, Cantrixil blocks the survival pathway pERK.  The combination of these two cellular effects (down-regulation of pro-survival and up-regulation of pro-death pathways) provides a unique advantage to target chemo-resistant cancer stem cells.

Cantrixil is due to enter its first-in-man study in late-2015.  The study will enroll patients with the terminal condition, malignant ascites, associated with late-stage abdominal carcinomatosis of various types of cancer, but mainly targeting ovarian cancer and colo-rectal cancer.

About Cantrixil

Cantrixil is a cyclodextrin envelope containing the active ingredient, TRXE-002. The construct has been designed as an intra-cavity chemotherapy to be injected directly into the peritoneal and pleural cavities without causing local irritation or toxicity. Its purpose is to achieve high drug levels in the environment in which the cancer is spreading through the migration of the cancer stem cells are spreading. The ultimate primary indication of Cantrixil to be sought is first-line therapy of early-stage cancers of the abdominal cavity (eg. ovarian, uterine, colo-rectal and gastric carcinomas). Cantrixil will enter the clinic in later-stage cancers where the abdominal carcinomatosis has resulted in the terminal condition of malignant ascites.

Cantrixil is owned by CanTx, Inc.

About TRXE-002

TRXE-002 is a small molecule cytotoxic belonging to a family of compounds whose anti-cancer function is based on various biological effects including inhibition of trans-membrane electron-transfer mechanisms. TRXE-002 is pan anti-cancer acting, resulting in caspase-dependent apoptosis of both stem cell-like cancer cells and their daughter cancer cells. The compound has a high therapeutic index with little cytotoxic effect on non-tumor cells.

About CanTx, Inc.

CanTx is a joint venture company between Novogen and Yale University. Novogen has licensed the drug candidate, TRXE-002, to CanTx for use in Cantrixil. CanTx is based in New Haven, CT.

Further information is available on www.can-tx.com

About Novogen Limited

Novogen is a public, Australian-US drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, but with particular activity against the cancer stem (tumor-initiating) cell.

The ATM compounds target the micro-filament component of the cancer cell’s cytoskeleton and have been designed to combine with anti-microtubule drugs (taxanes, vinca alkaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.

The Company pipeline comprises two SBP drug candidates (TRXE-002, TRXE-009) and one ATM drug candidate (Anisina).

Further information is available on our website www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.  The Company has tried to identify such forward-looking statements by use of such words as “expects,” “appear,” “intends,” “hopes,” “anticipates,” “believes,” “could,” “should,” “would,”  “may,” “target,”  “evidences” and “estimates,” and other similar expressions, but these words are not the exclusive means of identifying such statements.  Such statements include, but are not limited to any statements relating to the Company’s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited to, Cantrixil and TRXE-002, and any other statements that are not historical facts.  Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to Cantrixil and TRXE-002, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug compounds, including, but not limited to, Cantrixil and TRXE-002, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company’s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil and TRXE-002, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K.  Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release.  Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

Health Care

Green Cross and Nanolek Announce Strategic Partnership for Biologics Commercialisation in Russia

admin

YONGIN, South Korea, March 26, 2014 /PRNewswire/ — Green Cross, a South Korean biopharmaceutical company, and Nanolek, a Russian pharmaceutical company, today announced that they have entered into a strategic partnership agreement for the commercialisation of Green Cross’ biologics in the Russian market.

Under the terms of the agreement, Nanolek will obtain marketing authorisations and set up the production of a number of Green Cross’ biologics. The production will be organised at Nanolek’s facility, a state-of-art biopharmaceutical complex built and equipped in compliance with EU GMP standards and launched in December 2014.

“This partnership is a perfect strategic fit for Green Cross’ global business model,” said EC Huh, Ph. D., president of Green Cross Corporation. “We are excited to work with the team at Nanolek, and to share in the longer-term commercial success of Green Cross’ products as it enters Russia.”

“Our project with Green Cross will make socially significant drugs more accessible and minimize the state’s financial burden for the procurement of these drugs outside of Russia,” said Mikhail Nekrasov, CEO of Nanolek. “Making possible the domestic production of a number of biopharmaceuticals is our contribution to the implementation of the government policy in developing the Russian pharmaceutical industry.”

Russia’s pharmaceutical market is one of the most attractive in the emerging European region, mainly due to its absolute size, plus a growing economy and increasing government investment in healthcare, according to a report from Business Monitor International. The Russian market is set to grow at twice the pace of the global pharmaceutical market, with growth estimates around 10-15% annually reaching an approximate market value of $43-60 billion by 2020.

About Green Cross

Green Cross provides total healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, Green Cross specialises in the development and manufacturing of plasma-derivatives, vaccines and recombinant proteins.

About Nanolek

Nanolek is a Russian fast-growing pharmaceutical company which aims to become one of the market leaders in the production of innovative biotechnological products and modern vaccines, stimulating the creation of the national bio-economy and amplifying the country’s biosafety.

This release includes forward-looking statements concerning Green Cross’ strategic partnership with Nanolek, the commercialization of the company’s biologics in Russia. The statements are based on assumptions about many important factors. The company does not undertake to update its forward-looking statements.

Health Care

Philips and Mount Sinai Health System collaborate to advance clinical research through new digital pathology database and analytics

admin

EINDHOVEN, The Netherlands and NEW YORK, March 24, 2015 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA) today announced a joint development agreement with the Mount Sinai Health System, an integrated health system in New York, to create a state-of-the-art digital image repository of patient tissue samples and innovative data analytics to pursue the discovery of new tissue-based tests and unlock pathology data. The collaboration aims to advance clinical research and ultimately enable better care for complex diseases, including cancer.

Photo – http://photos.prnewswire.com/prnh/20150324/184024
Logo – http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

Pathology, including the examination of patient tissue samples, is one of the corner stones of modern medicine. The Mount Sinai Health System comprises seven hospital campuses serving approximately 170,000 inpatients and 2.6 million outpatients annually. Over the years, these sites have collectively stored hundreds of thousands of tissue samples in the form of glass tissue slides. Philips and Mount Sinai will now start to create a comprehensive digital image repository containing the digital scans of all these glass tissue slides. Ultimately, these data will be made accessible to researchers. By integrating, analyzing and presenting the data available from whole slide pathology images, clinical laboratory services, genetic analysis, radiology, and surgical and molecular pathology, Philips and Mount Sinai believe the unique insights obtained will enable the development of predictive analytics to help personalize patient care.

“The digitization of pathology gives us the unprecedented opportunity to access vast amounts of unlocked data and view it within the context of other images, results and clinical information,” said Frans van Houten, CEO Royal Philips. “It is our vision that our improved understanding of these data will help us enable better, more individualized care with greater confidence.”

“This collaboration with Philips has the potential to help drive a new paradigm in healthcare that includes the optimization of treatment efficacy and superior clinical outcomes,” said Dr. Carlos Cordon-Cardo M.D., Ph.D., Chairman of the Department of Pathology at the Mount Sinai Health System. “Our ultimate goal with this initiative is to translate data into knowledge to maximize personalized patient management.”

Mount Sinai is committed to partnering with industry to develop innovative therapies and diagnostics that improve the lives of patients worldwide. The terms of this collaboration agreement were managed by Mount Sinai Innovation Partners, the technology development and commercialization group for the Mount Sinai Health System.

For further information, please contact:

Philips:
Hans Driessen
Philips Digital Pathology Solutions
Tel: +31 6 10 610 417
E-mail: hans.driessen@philips.com

Steve Klink
Philips Group Communications
Tel.: +31 6 1088 8824
E-mail: steve.klink@philips.com

Mount Sinai Health System:
Sid Dinsay
Mount Sinai Health System Press Office
Tel: +1 212 241 9200
E-mail: sid.dinsay@mountsinai.org

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report. For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 105,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at www.philips.com/newscenter.

Health Care

Nestle Waters and Project WET Sign New 4-year Partnership and Come Together Again Globally for World Water Day on March 22nd, 2015

admin

PARIS, March 16, 2015 /PRNewswire/ — World Water Day, organized each year on March 22nd by the United Nations, provides an opportunity for Nestle Waters and Project WET (Water Education for Teachers) to raise awareness about the importance of water conservation and hydration.

To view the Multimedia News Release, please click:
http://www.multivu.com/players/English/7463151-nestle-waters-wet-world-water-day/

Nestle Waters and the non-governmental organization Project WET have renewed their global partnership, facilitating the continued expansion of water education amongst educators and children around the world for another four years.  

“Two decades of support from Nestle Waters have enabled Project WET to bring hands-on, action-oriented water education to people in places that we could not have reached on our own. We are eager to continue to expand the scope of our work with Nestle Waters in this renewed partnership,” says Dennis Nelson, President and CEO of Project WET Foundation. 

Project WET  

Project WET is a US-based NGO that develops educational tools to increase water literacy around the world amongst educators and children.

20-year partnership: Nestle Waters first partnered with Project WET in 1992

#1 global water education organization

More than 30 years of experience in water education

300 original science teaching methods

Project WET Foundation

WWD 2010 – 2015 

2015  

34 countries mobilized
700* employees involved
9000* children educated
10 lessons

2010 

18 countries mobilized
169 employees involved
4645 children educated
8 lessons

*estimated data

About Nestle Waters: Founded in 1992, Nestle Waters is the water division of the Nestle Group. Nestle Waters employs more than 30,000 people and is present in 130 countries with a portfolio of more than 59 brands including Nestle Pure Life, Perrier, S. Pellegrino, Poland Spring, Vittel, Buxton, Erikli.

For more information on Nestle Waters

For more information on World Water Day

Video: http://www.multivu.com/players/English/7463151-nestle-waters-wet-world-water-day/